Undergone imaging study for metastatic prostate cancer ≤ 3 months.
ECOG performance status ≥ 3.
Known malignant pleural effusions or ascites.
Current or prior treatment with investigational therapy for M0 Castration-Resistant Prostate Cancer (Taxotere (docetaxel), Provenge® (sipuleucel-T), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Jevtana (cabazitaxel), or Xofigo (radium Ra 223 dichloride).
